Neutrophil to lymphocyte ratio as a prognosis biomarker of PRRT in NET patients

Purpose Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE is a palliative therapeutic option for advanced Neuroendocrine Tumors (NETs). Prognostic factors can predict long-term outcomes and determine response to therapy. Among those already explored, biomarkers from full blood count,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Endocrine 2022, Vol.78 (1), p.177-185
Hauptverfasser:	de Lima, Beatriz Arruda Matheos, da Silva, Rinaldo Gonçalves, Carroll, Cibele, Vilhena, Bruno, Perez, Carolina, Felix, Renata, Carneiro, Michel, Neto, Luiz Machado, Vaisman, Fernanda, Corbo, Rossana, Pujatti, Priscilla Brunelli, Bulzico, Daniel
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomarkers Blood tests Diabetes Endocrinology Humanities and Social Sciences Internal Medicine Leukocytes (neutrophilic) Lymphocytes Medical prognosis Medical records Medicine Medicine & Public Health multidisciplinary Neuroendocrine tumors Neutrophils Original Article Patients Prognosis Radiation therapy Science Solid tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!